Prognostic factors for recurrence in resected pancreatic adenocarcinoma: A single-center experience.

e14541 Background: The aim of the study was to determine prognostic factors for recurrence in resected pancreatic cancer. Methods: We analyzed retrospectively 47 patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma, from January 2006 to July 2010. Demographic (age, sex), surgical (type of resection), pathological data (grading, TNM stage, lymph node ratio, presence of metastatic lymph nodes, number of lymph nodes harvested, R status, perineural and vascular invasion) and type of therapy (surgery alone versus surgery plus adjuvant treatment) were evaluated. Results: Adjuvant chemotherapy was performed in 28 patients: 23 received gemcitabine (GEM) alone (1,000 mg/mq die 1-8-15 every 28) and 5 GEM plus cisplatin (CDDP) (75 mg/mq die 1 every 28). Radiotherapy was preformed only in 9 patients: 6 associated with GEM alone and 3 with GEM plus CDDP. Median follow-up was 16 months. Total recurrences were 34 out of 47 patients (72.3%): local relapse were 10 (29.4 %) and distant metastase...